HIV molecular immunology database
Found 1 matching record:
| HXB2 Location | gp160(786-794) | gp160 Epitope Map
View variants at this location |
|||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Epitope |
GRRGWEILK
|
Epitope Alignment | |||||||||||||||||||||||||||||||||||||||||||
| Variants |
|
||||||||||||||||||||||||||||||||||||||||||||
| Epitope Name | GK9 | ||||||||||||||||||||||||||||||||||||||||||||
| Species (MHC/HLA) | humanized mouse | ||||||||||||||||||||||||||||||||||||||||||||
Showing all: 14 variant(s).
| Variant ID. | 4983 |
|---|---|
| Epitope Seq. | GRRGWEILK |
| Variant Seq. | GhRGWEILK |
| Mutations | R/H |
| Epitope Location | R2H |
| HXB2 Location | R787H |
| Mutation Type | E: escape documented in this paper IE: inferred escape OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Longitudinal study |
| Note | At 12 weeks post HIV-1JR-CSF-infection, variant GhRGWEILK was observed in 2/3 PBS control, 4/7 GFP control and 3/7 Gag-immunized mice with a frequency per mouse of 11-78%. |
| Variant ID. | 4984 |
|---|---|
| Epitope Seq. | GRRGWEILK |
| Variant Seq. | GlRGWEILK |
| Mutations | R/L |
| Epitope Location | R2L |
| HXB2 Location | R787L |
| Mutation Type | E: escape documented in this paper IE: inferred escape OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Longitudinal study |
| Note | At 12 weeks post HIV-1JR-CSF-infection, variant GlRGWEILK was observed in 1/3 PBS control, 0/7 GFP control and 1/7 Gag-immunized mice with a frequency per mouse of 16-35%. |
| Variant ID. | 4985 |
|---|---|
| Epitope Seq. | GRRGWEILK{YWW} |
| Variant Seq. | GlRGWEILK{Y-W} |
| Mutations | W/- R/L |
| Epitope Location | W+2- R2L |
| HXB2 Location | W796- R787L |
| Mutation Type | E: escape documented in this paper IE: inferred escape OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Longitudinal study |
| Note | At 12 weeks post HIV-1JR-CSF-infection, variant GlRGWEILK{Y-W} was observed in 6% of the sequencing reads in 1/7 Gag-immunized mice but not in any of the 3 PBS control or 7 GFP control mice. |
| Variant ID. | 4986 |
|---|---|
| Epitope Seq. | GRRGWEILK |
| Variant Seq. | GhRGWkILK |
| Mutations | R/H E/K |
| Epitope Location | R2H E6K |
| HXB2 Location | R787H E791K |
| Mutation Type | E: escape documented in this paper IE: inferred escape OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Longitudinal study |
| Note | At 12 weeks post HIV-1JR-CSF-infection, variant GhRGWkILK was observed in 5% of the sequencing reads in 1/7 GFP control mice but not in any of the 3 PBS control or 7 Gag-immunized mice. |
| Variant ID. | 4987 |
|---|---|
| Epitope Seq. | GRRGWEILK |
| Variant Seq. | GRRGrEILK |
| Mutations | W/R |
| Epitope Location | W5R |
| HXB2 Location | W790R |
| Mutation Type | E: escape documented in this paper IE: inferred escape OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Longitudinal study |
| Note | At 12 weeks post HIV-1JR-CSF-infection, variant GRRGrEILK was observed in 1/3 PBS control, 3/7 GFP control and 1/7 Gag-immunized mice with a frequency per mouse of 6-40%. |
| Variant ID. | 4988 |
|---|---|
| Epitope Seq. | GRRGWEILK |
| Variant Seq. | GRRGWgILK |
| Mutations | E/G |
| Epitope Location | E6G |
| HXB2 Location | E791G |
| Mutation Type | E: escape documented in this paper IE: inferred escape OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Longitudinal study |
| Note | At 12 weeks post HIV-1JR-CSF-infection, variant GRRGWgILK was observed in 1/3 PBS control, 3/7 GFP control and 3/7 Gag-immunized mice with a frequency per mouse of 6-74%. |
| Variant ID. | 4989 |
|---|---|
| Epitope Seq. | GRRGWEILK |
| Variant Seq. | GRRGWElLK |
| Mutations | I/L |
| Epitope Location | I7L |
| HXB2 Location | I792L |
| Mutation Type | E: escape documented in this paper IE: inferred escape OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Longitudinal study |
| Note | At 12 weeks post HIV-1JR-CSF-infection, variant GRRGWElLK was observed in 1/3 PBS control, 1/7 GFP control and 1/7 Gag-immunized mice with a frequency per mouse of 5-12%. |
| Variant ID. | 4990 |
|---|---|
| Epitope Seq. | GRRGWEILK |
| Variant Seq. | GRRGWkILK |
| Mutations | E/K |
| Epitope Location | E6K |
| HXB2 Location | E791K |
| Mutation Type | E: escape documented in this paper IE: inferred escape OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Longitudinal study |
| Note | At 12 weeks post HIV-1JR-CSF-infection, variant GRRGWkILK was observed in 1/3 PBS control, 2/7 GFP control and 3/7 Gag-immunized mice with a frequency per mouse of 6-33%. |
| Variant ID. | 4991 |
|---|---|
| Epitope Seq. | GRRGWEILK |
| Variant Seq. | GRRGWEtLK |
| Mutations | I/T |
| Epitope Location | I7T |
| HXB2 Location | I792T |
| Mutation Type | E: escape documented in this paper IE: inferred escape OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Longitudinal study |
| Note | At 12 weeks post HIV-1JR-CSF-infection, variant GRRGWEtLK was observed in 1/3 PBS control, 4/7 GFP control and 4/7 Gag-immunized mice with a frequency per mouse of 7-51%. |
| Variant ID. | 4992 |
|---|---|
| Epitope Seq. | GRRGWEILK |
| Variant Seq. | GRRGWEsLK |
| Mutations | I/S |
| Epitope Location | I7S |
| HXB2 Location | I792S |
| Mutation Type | E: escape documented in this paper IE: inferred escape OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Longitudinal study |
| Note | At 12 weeks post HIV-1JR-CSF-infection, variant GRRGWEsLK was observed in 6% of the sequencing reads in 1/7 GFP control mice but not in any of the 3 PBS control or 7 Gag-immunized mice. |
| Variant ID. | 4993 |
|---|---|
| Epitope Seq. | GRRGWEILK |
| Variant Seq. | GRRGWEvLK |
| Mutations | I/V |
| Epitope Location | I7V |
| HXB2 Location | I792V |
| Mutation Type | E: escape documented in this paper IE: inferred escape OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Longitudinal study |
| Note | At 12 weeks post HIV-1JR-CSF-infection, variant GRRGWEvLK was observed in 0/3 PBS control, 4/7 GFP control and 1/7 Gag-immunized mice with a frequency per mouse of 8-53%. |
| Variant ID. | 4994 |
|---|---|
| Epitope Seq. | GRRGWEILK |
| Variant Seq. | GRRGWEnLK |
| Mutations | I/N |
| Epitope Location | I7N |
| HXB2 Location | I792N |
| Mutation Type | E: escape documented in this paper IE: inferred escape OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Longitudinal study |
| Note | At 12 weeks post HIV-1JR-CSF-infection, variant GRRGWEnLK was observed in 28% of the sequencing reads in 1/7 Gag-immunized mice but not in any of the 3 PBS control or 7 GFP control mice. |
| Variant ID. | 4995 |
|---|---|
| Epitope Seq. | GRRGWEILK |
| Variant Seq. | GRRGWdILK |
| Mutations | E/D |
| Epitope Location | E6D |
| HXB2 Location | E791D |
| Mutation Type | E: escape documented in this paper IE: inferred escape OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Longitudinal study |
| Note | At 12 weeks post HIV-1JR-CSF-infection, variant GRRGWdILK was observed in 11% of the sequencing reads in 1/7 Gag-immunized mice but not in any of the 3 PBS control or 7 GFP control mice. |
| Variant ID. | 4996 |
|---|---|
| Epitope Seq. | GRRGWEILK |
| Variant Seq. | GRRGgEILK |
| Mutations | W/G |
| Epitope Location | W5G |
| HXB2 Location | W790G |
| Mutation Type | E: escape documented in this paper IE: inferred escape OV: observed variant |
| Epitope Subtype | B |
| Variant Subtype | B |
| Method | Longitudinal study |
| Note | At 12 weeks post HIV-1JR-CSF-infection, variant GRRGgEILK was observed in 39% of the sequencing reads in 1/7 Gag-immunized mice but not in any of the 3 PBS control or 7 GFP control mice. |
Claiborne2019 Daniel T. Claiborne, Timothy E. Dudek, Colby R. Maldini, Karen A. Power, Musie Ghebremichael, Edward Seung, Elizabeth F. Mellors, Vladimir D. Vrbanac, Katharine Krupp, Abigail Bisesi, Andrew M. Tager, David M. Knipe, Christian L. Boutwell, and Todd M. Allen. Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Reduces Acute HIV-1 Viremia. J. Virol., 93(20), 15 Oct 2019. PubMed ID: 31375576. Show all entries for this paper.